Mesoblast (MESO) EBT (2015 - 2023)
Mesoblast recorded quarterly EBT of -$22.0 million in Q2 2023, down 17.77% quarter-over-quarter from -$18.6 million in Q1 2023, and down 2.1% year-over-year from -$22.4 million in Q2 2022.
Mesoblast's EBT history runs 9 years deep, the most recent figure standing at -$22.0 million for Q2 2023.
- In Q2 2023, EBT fell 2.1% year-over-year to -$22.0 million; the TTM figure through Jun 2023 stood at -$82.1 million (up 10.36% YoY), while the FY2025 annual figure was -$101.8 million, down 15.5% from the prior year.
- EBT came in at -$22.0 million for Q2 2023 at Mesoblast, down from -$18.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$7.4 million in Q3 2019 to a low of -$35.9 million in Q2 2020.
- A 5-year average of -$22.9 million and a median of -$23.3 million in 2019 frame the typical range for EBT.
- Across the five-year window, EBT jumped 63.3% in 2019 and sank 240.8% in 2020, its largest moves.
- Mesoblast's EBT stood at -$26.9 million in 2019, then grew by 4.6% to -$25.6 million in 2020, then dropped by 1.59% to -$26.0 million in 2021, then rose by 5.64% to -$24.6 million in 2022, then grew by 10.58% to -$22.0 million in 2023.
- According to Business Quant data, EBT over the past three periods registered -$22.0 million, -$18.6 million, and -$24.6 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -21.96 Mn |
| Mar 31, 2023 | -18.65 Mn |
| Dec 31, 2022 | -24.56 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -21.51 Mn |
| Mar 31, 2022 | -21.35 Mn |
| Dec 31, 2021 | -26.03 Mn |
| Sep 30, 2021 | -22.71 Mn |
| Jun 30, 2021 | -22.13 Mn |
| Mar 31, 2021 | -26.61 Mn |
| Dec 31, 2020 | -25.62 Mn |
| Sep 30, 2020 | -25.27 Mn |
| Jun 30, 2020 | -35.87 Mn |
| Mar 31, 2020 | -17.22 Mn |
| Dec 31, 2019 | -26.85 Mn |
| Sep 30, 2019 | -7.42 Mn |
| Jun 30, 2019 | -23.90 Mn |
| Mar 31, 2019 | -27.18 Mn |
| Dec 31, 2018 | -27.47 Mn |
| Sep 30, 2018 | -20.21 Mn |
| Jun 30, 2018 | -21.86 Mn |
| Mar 31, 2018 | -24.56 Mn |
| Dec 31, 2017 | -9.64 Mn |
| Sep 30, 2017 | -9.92 Mn |
| Jun 30, 2017 | -31.26 Mn |
| Mar 31, 2017 | -12.88 Mn |
| Dec 31, 2016 | -23.18 Mn |
| Sep 30, 2016 | -22.90 Mn |
| Jun 30, 2016 | -34.21 Mn |
| Mar 31, 2016 | -21.12 Mn |
| Dec 31, 2015 | -22.33 Mn |